Celldex Therapeutics (NASDAQ:CLDX - Get Free Report) is projected to issue its quarterly earnings data before the market opens on Monday, February 24th. Analysts expect the company to announce earnings of ($0.73) per share and revenue of $1.31 million for the quarter.
Celldex Therapeutics stock opened at $22.70 on Monday. The firm has a market capitalization of $1.51 billion, a P/E ratio of -8.83 and a beta of 1.60. The stock has a fifty day moving average price of $24.70 and a 200 day moving average price of $29.73. Celldex Therapeutics has a 52 week low of $20.91 and a 52 week high of $53.18.
CLDX has been the subject of several analyst reports. UBS Group initiated coverage on Celldex Therapeutics in a research note on Thursday. They issued a "buy" rating and a $44.00 target price for the company. HC Wainwright reiterated a "buy" rating and issued a $80.00 target price on shares of Celldex Therapeutics in a research note on Thursday, December 19th. Finally, Cantor Fitzgerald reiterated an "overweight" rating and issued a $67.00 target price on shares of Celldex Therapeutics in a research note on Wednesday, January 29th. Two equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $60.22.
View Our Latest Report on Celldex Therapeutics
Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you make your next trade, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis.
Our team has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and none of the big name stocks were on the list.
They believe these five stocks are the five best companies for investors to buy now...
See The Five Stocks Here
Before you consider Celldex Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Celldex Therapeutics wasn't on the list.
While Celldex Therapeutics currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.